Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires

Merck is buying oncology institution Terns Pharmaceuticals successful a woody valued astatine astir $6.7 cardinal arsenic the pharmaceutical elephantine works connected beefing up its crab portfolio earlier a cardinal patent connected its crab cause Keytruda expires successful 2 years